or Try an Advanced Search...

    Fibroblast Growth Factor Receptor Stocks List

    Symbol Grade Name % Change
    BPMC C Blueprint Medicines Corporation 1.10
    TYRA F Tyra Biosciences, Inc. -0.54
    BBIO F BridgeBio Pharma, Inc. 1.74
    RLAY F Relay Therapeutics, Inc. 0.43
    View As Page of Charts
    Related Industries: Biotechnology
    Related Stock Lists: Tyrosine Kinase Receptors Tyrosine Kinase Cancer Cell Biology Fibroblast Growth Factor Protein Kinase Inhibitor Achondroplasia Advanced Solid Tumors Amyloid Amyloidosis Biology Biopharmaceutical Bladder Cancer Cardiomyopathy Cell Signaling Clinical Development Clusters Of Differentiation Congenital Adrenal Hyperplasia Drug Discovery Enzymes

    Related ETFs - A few ETFs which own one or more of the above listed Fibroblast Growth Factor Receptor stocks.

    Symbol Grade Name Weight
    CANC D Tema Oncology ETF 4.74
    WDNA D WisdomTree BioRevolution Fund 4.03
    HRTS D Tema Cardiovascular and Metabolic ETF 3.69
    CNCR F Loncar Cancer Immunotherapy ETF 3.65
    PBE D PowerShares Dynamic Biotech & Genome 2.91
    View all Fibroblast Growth Factor Receptor ETFs...
    Compare ETFs
    Compare CANC to CNCR Compare CANC to WDNA Compare WDNA to PBE

        Fibroblast Growth Factor Receptor Stocks Recent News

        Date Stock Title
        Nov 20 RLAY Down -27.93% in 4 Weeks, Here's Why Relay Therapeutics (RLAY) Looks Ripe for a Turnaround
        Nov 19 BBIO BridgeBio Pharma's Acoramidis Shows Competitive Edge Against Pfizer's Tafamidisa In Lucrative But Competitive ATTR-CM Market
        Nov 19 RLAY Down -23.95% in 4 Weeks, Here's Why Relay Therapeutics (RLAY) Looks Ripe for a Turnaround
        Nov 19 BBIO The Consensus EPS Estimates For BridgeBio Pharma, Inc. (NASDAQ:BBIO) Just Fell Dramatically
        Nov 18 BBIO Open-Label Extension Data Confirms Sustained Benefit of Acoramidis on Cardiovascular Outcomes, Including Statistically Significant Reduction in ACM Within 36 Months
        Nov 18 BBIO BridgeBio Pharma Announces Publication in the New England Journal of Medicine of Phase 2 PROPEL 2 Study of Infigratinib for Children Living with Achondroplasia
        Nov 15 BPMC Blueprint Medicines' Growth With AYVAKIT And Next-Gen Oncology Drugs
        Nov 14 BPMC Blood Cancer-Focused Blueprint Medicines Could Be 'Attractive Target For Partnerships': Analyst
        Related Industries: Biotechnology
        Related Stock Lists: Tyrosine Kinase Receptors Tyrosine Kinase Cancer Cell Biology Fibroblast Growth Factor Protein Kinase Inhibitor Achondroplasia Advanced Solid Tumors Amyloid Amyloidosis Biology Biopharmaceutical Bladder Cancer Cardiomyopathy Cell Signaling Clinical Development Clusters Of Differentiation Congenital Adrenal Hyperplasia Drug Discovery Enzymes
        Fibroblast Growth Factor Receptor

        Fibroblast Growth Factor Receptor (FGFR) is a family of cell surface receptors that bind to and respond to fibroblast growth factors (FGFs). FGFRs are involved in a variety of cellular processes, including cell proliferation, differentiation, migration, and survival. They are also involved in the development of many diseases, including cancer.

        Browse All Tags